Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy-Reference-Cited by-同舟云学术

Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy

Published:2021-03 Issue:1 Volume:67 Page:
ISSN:2724-5985
Container-title:Minerva Gastroenterology
language:
Short-container-title:Minerva Gastroenterol

Author:

BATTISTELLA Sara,LYNCH Erica N.,GAMBATO Martina,ZANETTO Alberto,PELLONE Monica,SHALABY Sarah,SCIARRONE Salvatore S.,FERRARESE Alberto,GERMANI Giacomo,SENZOLO Marco,BURRA Patrizia,RUSSO Francesco P.

Publisher

Edizioni Minerva Medica

Subject

Gastroenterology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://www.minervamedica.it/pdf.php?cod=R08Y2021N01A0038

Reference70 articles.

1. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine

2. Impact of therapy on the outcome of chronic hepatitis B

3. The global health burden of infection-associated cancers in the year 2002

4. HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS

5. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression of liver disease and associated risk of hepatocellular carcinoma;Hepatoma Research;2024-03-28

2. Exosomes loading Tapasin enhance T cell immune response by autophagy to inhibit HBV replication;Journal of Medical Virology;2023-04

3. Iodide mumps in a patient with liver cirrhosis without renal impairment;Minerva Gastroenterology;2022-12

4. Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma;Minerva Gastroenterology;2022-12

5. Role of epigenetic modification in interferon treatment of hepatitis B virus infection;Frontiers in Immunology;2022-10-17